RxSight (RXST) Cash & Equivalents (2020 - 2026)

RxSight (RXST) has 7 years of Cash & Equivalents data on file, last reported at $17.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 37.24% year-over-year to $17.6 million; the trailing twelve-month figure through Mar 2026 stood at $17.6 million (down 37.24% YoY), and the FY2025 full-year result was $19.9 million, down 91.59% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $17.6 million, down from $19.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $237.2 million in Q4 2024 and bottomed at $9.9 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $102.9 million (2022), against an average of $89.7 million.
• Peak annual rise in Cash & Equivalents reached 830.66% in 2025, while the deepest fall reached 91.59% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $102.9 million in 2022, then grew by 18.55% to $122.0 million in 2023, then surged by 94.48% to $237.2 million in 2024, then sank by 91.59% to $19.9 million in 2025, then fell by 11.91% to $17.6 million in 2026.
• The last three Cash & Equivalents figures came in at $17.6 million (Q1 2026), $19.9 million (Q4 2025), and $29.6 million (Q3 2025), per Business Quant data.

Peer Comparison